You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, June 2015
|
| DOI | 10.1186/s40425-015-0068-y |
| Pubmed ID | |
| Authors |
Hubert Kübler, Birgit Scheel, Ulrike Gnad-Vogt, Kurt Miller, Wolfgang Schultze-Seemann, Frank vom Dorp, Giorgio Parmiani, Christian Hampel, Steffen Wedel, Lutz Trojan, Dieter Jocham, Tobias Maurer, Gerd Rippin, Mariola Fotin-Mleczek, Florian von der Mülbe, Jochen Probst, Ingmar Hoerr, Karl-Josef Kallen, Thomas Lander, Arnulf Stenzl |
| Abstract |
CV9103 is a prostate-cancer vaccine containing self-adjuvanted mRNA (RNActive®) encoding the antigens PSA, PSCA, PSMA, and STEAP1. This phase I/IIa study evaluated safety and immunogenicity of CV9103 in patients with advanced castration-resistant prostate-cancer. 44 Patients received up to 5 intra-dermal vaccinations. Three dose levels of total mRNA were tested in Phase I in cohorts of 3-6 patients to determine a recommended dose. In phase II, 32 additional patients were treated at the recommended dose. The primary endpoint was safety and tolerability, the secondary endpoint was induction of antigen specific immune responses monitored at baseline and at weeks 5, 9 and 17. The most frequent adverse events were grade 1/2 injection site erythema, injection site reactions, fatigue, pyrexia, chills and influenza-like illness. Possibly treatment related urinary retention occurred in 3 patients. The recommended dose was 1280 μg. A total of 26/33 evaluable patients treated at 1280 μg developed an immune response, directed against multiple antigens in 15 out of 33 patients. One patient showed a confirmed PSA response. In the subgroup of 36 metastatic patients, the Kaplan-Meier estimate of median overall survival was 31.4 months [95 % CI: 21.2; n.a]. The self-adjuvanted RNActive® vaccine CV9103 was well tolerated and immunogenic. The technology is a versatile, fast and cost-effective platform allowing for creation of vaccines. The follow-up vaccine CV9104 including the additional antigens prostatic acid phosphatase (PAP) and Muc1 is currently being tested in a randomized phase IIb trial to assess the clinical benefit induced by this new vaccination approach. EU Clinical Trials Register: EudraCT number 2008-003967-37, registered 27 Jan 2009. |
X Demographics
The data shown below were collected from the profiles of 46 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 10 | 22% |
| United Kingdom | 3 | 7% |
| Australia | 2 | 4% |
| France | 2 | 4% |
| Denmark | 1 | 2% |
| Madagascar | 1 | 2% |
| Canada | 1 | 2% |
| Germany | 1 | 2% |
| Italy | 1 | 2% |
| Other | 0 | 0% |
| Unknown | 24 | 52% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 38 | 83% |
| Scientists | 2 | 4% |
| Practitioners (doctors, other healthcare professionals) | 2 | 4% |
| Science communicators (journalists, bloggers, editors) | 1 | 2% |
| Unknown | 3 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 245 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | <1% |
| Unknown | 244 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 42 | 17% |
| Student > Ph. D. Student | 34 | 14% |
| Student > Bachelor | 34 | 14% |
| Other | 19 | 8% |
| Student > Master | 17 | 7% |
| Other | 34 | 14% |
| Unknown | 65 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 38 | 16% |
| Biochemistry, Genetics and Molecular Biology | 35 | 14% |
| Medicine and Dentistry | 34 | 14% |
| Immunology and Microbiology | 22 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 13 | 5% |
| Other | 33 | 13% |
| Unknown | 70 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 64. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 December 2023.
All research outputs
#679,523
of 25,658,541 outputs
Outputs from Journal for Immunotherapy of Cancer
#155
of 3,479 outputs
Outputs of similar age
#7,197
of 264,564 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#1
of 16 outputs
Altmetric has tracked 25,658,541 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,479 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.7. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,564 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.